Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
These re-agent and diagnostic test kits come with 99.7% accuracy
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Subscribe To Our Newsletter & Stay Updated
